C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.430
-0.040 (-1.62%)
At close: Dec 15, 2025, 4:00 PM EST
2.449
+0.019 (0.79%)
After-hours: Dec 15, 2025, 6:57 PM EST
C4 Therapeutics Employees
C4 Therapeutics had 110 employees as of December 31, 2024. The number of employees decreased by 35 or -24.14% compared to the previous year.
Employees
110
Change (1Y)
-35
Growth (1Y)
-24.14%
Revenue / Employee
$273,709
Profits / Employee
-$1,082,555
Market Cap
235.50M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 110 | -35 | -24.14% |
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | 99 | 11 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CCCC News
- 19 days ago - Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha
- 20 days ago - C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 5 weeks ago - C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 3 months ago - C4 Therapeutics, Inc. - Special Call - Seeking Alpha
- 3 months ago - C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting - GlobeNewsWire